IDEAYA Biosciences (IDYA) concentration risks

The company's only disclosed concentration is a pipeline dependency centered on a single clinical program. Darovasertib — an oral, potent and selective small molecule inhibitor of protein kinase C (PKC) and the company's most advanced clinical program — is disclosed as the leading asset in the pipeline, establishing it as a high-share exposure by disclosed size with a mixed character. The concentration is mixed because, at this clinical stage, a single lead asset is both typical of the development-stage company model (structural) and constitutes a genuine single-program dependency where most of the investment thesis is contingent on one program's clinical and regulatory outcome (dependency). No revenue percentages are applicable since the company is pre-commercial; the high-share sizing reflects the fact that the leading clinical program represents a large share of the company's disclosed pipeline value and strategic focus rather than a share of revenue. The filing does not quantify the share of spending, clinical milestones, or valuation attributable to darovasertib explicitly, but its designation as the "most advanced" program establishes its primacy. There are no disclosed customer, geographic, or supplier concentrations beyond this pipeline position. For a clinical-stage biopharmaceutical company, single-asset concentration of this type is the norm rather than an exception; the key monitoring variables are clinical data readouts and regulatory decisions for darovasertib, as these are the events most likely to move the investment verdict in either direction.

For the engine’s reasoning on IDYA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.